Study patient samples
Analyze immune-cell states, molecular defects, and disease-promoting programs in human tissue.
Choi Lab
Pioneering therapies for immune-related diseases.
The Choi Lab studies immune-cell defects in human disease and engineers new immunotherapy and cellular therapy strategies to reverse disease-promoting changes.
About the Lab
From human disease samples to engineered immune-cell therapies.
The Choi Lab develops novel immunotherapies by using high-dimensional approaches to study human disease samples, identify disease-promoting molecular defects in immune cells, and engineer ways to reverse those defects.
The lab’s work connects cancer immunology, autoimmune disease, T cell lymphoma, cellular therapy, single-cell biology, spatial analysis, and translational research.
Cancer immunologyAutoimmune diseaseT cell lymphomaCellular therapyPrecision medicine
Find actionable mechanisms
Connect genomic, single-cell, spatial, and functional data to reveal therapeutic opportunities.
Engineer new therapies
Translate discoveries into immune-engineering and cellular therapy strategies.
Research
View all researchResearch Areas
Project 01
T Cell Engineering
Learning from T cell biology and somatic mutations to design stronger adoptive cell therapies.
Learn more →
Project 02
Autoimmune Disease
Identifying molecular programs that drive pathogenic T cells in autoimmune disease.
Learn more →
Project 03
T Cell Lymphoma
Studying genomic drivers, signaling pathways, biomarkers, and therapeutic vulnerabilities.
Learn more →
Project 04
Precision Medicine
Using single-cell and spatial tools to understand disease progression and drug resistance.
Learn more →
Meet the PI
Jaehyuk Choi, M.D., Ph.D.
Inaugural Director of the Center for Cellular Therapies and Cancer Immunology and Vice Chair for Translational Research and Innovation in Dermatology.
Dr. Choi leads a research program focused on cancer immunology, autoimmune disease, T cell lymphoma, cellular therapy, and translational discovery.
Center Connection
Center for Cellular Therapies and Cancer Immunology
The Choi Lab is part of UT Southwestern’s Center for Cellular Therapies and Cancer Immunology, a Simmons Cancer Center initiative focused on immune engineering, cellular therapy, cancer immunology, and translational discovery.
Visit the CCTCI Center websiteLatest Updates
View all newsNews & Events
Research News
Scientists identify a potential root cause of lupus
Research on T cell imbalance and abnormal immune signaling may help explain lupus biology.
Read more →
Lab News
Choi recruited to lead new Center for Cellular Therapies and Cancer Immunology
Dr. Choi began his role leading a center focused on cellular therapies and cancer immunology.
Read more →
Research News
Cancerous T cells may reveal immunotherapy strategies
Lessons from malignant T cells may help guide the engineering of more powerful therapies.
Read more →
Podcasts & Media
View media
Listen in on the science.
Audio coverage and conversations about Choi Lab research, T cell engineering, immunotherapy, and T cell lymphoma.
Selected audio and media coverage.
Nature Podcast coverage and a Treating Blood Cancers interview featuring Choi Lab science.
Nature Podcast
Cancer’s power harnessed — lymphoma mutations supercharge T cells
Coverage of work showing how cancer-derived mutations can be used to strengthen therapeutic T cells without making them malignant.
Listen / read summary →
Treating Blood Cancers
Exploring Cutaneous T-Cell Lymphoma
Dr. Choi discusses CTCL diagnosis, emerging therapies, symptom management, disparities, and the value of multidisciplinary care.
Listen on iHeartRadio →Scientific Progress
View publicationsFeatured Publications
Addiction of primary cutaneous γδ T cell lymphomas to JAK/STAT signaling.
Original investigation; PMID 40231467.
View publication →
Pre-existing skin-resident CD8 and γδ T cell circuits mediate immune response in Merkel cell carcinoma and predict immunotherapy efficacy.
Original investigation; PMID 39058036.
View publication →
Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus.
Original investigation; PMID 38987586.
View publication →
Naturally occurring T cell mutations enhance engineered T cell therapies.
Original investigation; PMID 38326614.
View publication →
PD-1 instructs a tumor-suppressive metabolic program in T cell lymphoma.
Original investigation; tumor immunology and metabolism.
View publication →
BACH2 is a putative T cell lymphoma tumor suppressor.
Selected peer-reviewed publication.
View publication →
Primary cytotoxic T-cell lymphomas harbor targetable JAK/STAT pathway alterations.
Selected peer-reviewed publication.
View publication →
ZEB1 promotes pathogenic programs in cutaneous T cell lymphoma.
Selected peer-reviewed publication.
View publication →
Distinctive genomic features of HTLV-associated T cell disease.
Selected peer-reviewed publication.
View publication →
Genomic landscape of cutaneous T cell lymphoma and related diseases.
Selected peer-reviewed publication.
View publication →
Training and Collaboration
Build new approaches for immune-related disease.
We welcome inquiries from trainees, research staff, clinicians, and collaborators interested in immune engineering, cancer immunology, autoimmunity, cellular therapy, and translational science.
Join or collaborate